

University of Dundee

A rational approach to e-cigarettes

Britton, John; George, Jacob; Bauld, Linda; Agrawal, Sanjay ; Moxham, John ; Arnott, Deborah

Published in:
European Respiratory Journal

DOI:
[10.1183/13993003.00166-2020](https://doi.org/10.1183/13993003.00166-2020)

Publication date:
2020

Document Version
Peer reviewed version

[Link to publication in Discovery Research Portal](#)

Citation for published version (APA):

Britton, J., George, J., Bauld, L., Agrawal, S., Moxham, J., Arnott, D., McNeill, A., & Hopkinson, N. S. . (2020). A rational approach to e-cigarettes: challenging ERS policy on tobacco harm reduction . *European Respiratory Journal*, 55(5), [e2000166]. <https://doi.org/10.1183/13993003.00166-2020>

General rights

Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain.
- You may freely distribute the URL identifying the publication in the public portal.

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.



A rational approach to e-cigarettes - challenging ERS policy on tobacco harm reduction

Journal:	<i>European Respiratory Journal</i>
Manuscript ID	ERJ-00166-2020
Manuscript Type:	Correspondence
Date Submitted by the Author:	28-Jan-2020
Complete List of Authors:	<p>Britton, John; Univ of Nottingham, Resp Med</p> <p>George, Jacob; University of Dundee, Molecular and Cellular Medicine</p> <p>Bauld, Linda; The University of Edinburgh College of Medicine and Veterinary Medicine</p> <p>Agrawal, Sanjay; Institute for Lung Health, Department of Respiratory Medicine, Glenfield Hospital, Department of Infection, Immunity and Inflammation</p> <p>Moxham, John; King's College London, Faculty of Life Sciences and Medicine</p> <p>Arnott, Deborah; Action on Smoking and Health</p> <p>McNeill, Ann; King's College London, Institute of Psychiatry, Psychology & Neuroscience</p> <p>Hopkinson, Nicholas; Imperial College London, National Heart and Lung Institute</p>
Key Words:	tobacco, public health, e cigarettes
Abstract:	

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

A rational approach to e-cigarettes - challenging ERS policy on tobacco harm reduction

John Britton¹, Jacob George², Linda Bauld³, Sanjay Agrawal⁴, John Moxham⁵, Deborah Arnott⁶, Ann McNeill⁷,
Nicholas S Hopkinson⁸

¹UK Centre for Tobacco & Alcohol Studies, University of Nottingham, London, UK

²Molecular and Cellular Medicine, Dundee University, Scotland, UK

³Usher Institute, College of Medicine and Veterinary Medicine, University of Edinburgh, Scotland, UK

⁴Institute for Lung Health, University of Leicester, UK

⁵Faculty of Life Sciences and Medicine, King's College London, UK

⁶Action on Smoking and Health (ASH UK), London, UK

⁷Institute of Psychiatry, Psychology & Neuroscience, King's College London, UK

⁸National Heart and Lung Institute, Imperial College, London, UK

Corresponding Author: Dr Nicholas Hopkinson

National Heart and Lung Institute
Imperial College, London
Royal Brompton Hospital Campus
London SW3 6NP
ORCID iD 0000-0003-3235-0454
n.hopkinson@ic.ac.uk

Word count: 1493

1
2 The respiratory community is united in its desire to reduce and eliminate the harm caused by tobacco
3 smoking, which is at present on course to kill one billion people in the 21st century. The stated policy of the
4 European Respiratory Society is to strive “*constantly to promote strong and evidence-based policies to reduce*
5 *the burden of tobacco related diseases*”. In our view, the recent ERS Tobacco Control Committee statement
6 on tobacco harm reduction[1], though well-intentioned, appears to be based on a number of false premises
7 and draws its conclusions from a partial account of available data. It also presents a false dichotomy between
8 the provision of “conventional” tobacco control and harm reduction approaches. We therefore respond, in
9 turn, to the seven arguments presented against the adoption of harm reduction in the Committee’s
10 statement.
11
12
13
14
15
16
17
18
19
20
21
22
23

- 24 1. *The tobacco harm reduction strategy is based on incorrect claims that smokers cannot or will*
25 *not quit smoking.*
26
27
28
29
30

31 The strategy is in fact based on the need for additional measures to help the estimated 100 million smokers
32 in the European Union who still *have not* quit. Europe has the highest smoking prevalence of all the WHO
33 Regions[2] and business as usual has so far failed to help these individuals. Smoking rates are significantly
34 associated with economic disadvantage and ongoing failure to address this is a huge driver of health
35 inequality.
36
37
38
39
40
41
42
43

- 44 2. *The tobacco harm reduction strategy is based on undocumented assumptions that alternative nicotine*
45 *delivery products are highly effective as a smoking cessation aid.*
46
47
48
49
50

51 When smokers use a nicotine replacement product to substitute for cigarettes, even in the absence of
52 intention to quit, they are approximately twice as likely to proceed to quit smoking completely[3]. It would
53 be astonishing if nicotine delivered via e-cigarettes was uniquely ineffective in helping people to quit
54 smoking. In fact, in a definitive head-to-head randomised controlled clinical trial, electronic cigarettes proved
55 to be twice as effective as combination nicotine replacement therapy (NRT) when delivered as part of an
56
57
58
59
60

1
2 evidence-based smoking cessation intervention[4] and in a recently published smaller New Zealand trial, four
3
4 times more effective than nicotine patches alone[5]. Whether e-cigarettes are “highly effective” is a question
5
6 of definition, but it is not an “undocumented assertion” to observe that they are certainly at least as effective
7
8 as medicinal NRT[4, 5] .
9

10
11
12
13 3. *The tobacco harm reduction strategy is based on incorrect assumptions that smokers will replace*
14
15 *conventional cigarettes with alternative nicotine delivery products.*
16

17
18
19
20 Harm reduction strategies do not assume that *all* smokers will completely switch from tobacco cigarettes to
21
22 alternative products, any more than does the medicinally licensed strategy of using nicotine replacement
23
24 therapy to cut down on smoking. The strategy is instead based on an initial expectation, subsequently
25
26 supported by clear empirical evidence[6, 7], that an appreciable proportion will switch.
27

28
29
30
31 4. *The tobacco harm reduction strategy is based on undocumented assumptions that alternative nicotine*
32
33 *delivery products are generally harmless.*
34

35
36
37
38 No credible commentator has argued that reduced harm products are harmless. By definition, harm
39
40 reduction strategies are based on *reducing* rather than *eliminating* harm and the likelihood that there is some
41
42 risk from their long term use is explicitly acknowledged in statements on the subject[8-11]. However, the fact
43
44 that many of the elements found in tobacco smoke that are known to cause toxicity are either absent from
45
46 e-cigarette vapour or present at much lower levels[12] does support a substantial reduction in this risk.
47
48 Supportive clinical data in smokers who switch to vaping include rapid improvement in vascular endothelial
49
50 function[13], profound falls in systemic carcinogen levels to ones equivalent to ex-smokers using NRT[14]
51
52 and improvement in respiratory symptoms[4]. Understandable concerns over safety arising from the 2019
53
54 outbreak of vaping-related lung injury (EVALI) in the US have been alleviated by evidence it was caused by
55
56 vaping illicit products, in particular THC cut with vitamin E acetate[15].
57
58
59
60

- 1
2 5. *Alternative nicotine delivery products can have a negative impact on public health even if “stick-by-stick”*
3
4 *they turn out to be less harmful than conventional cigarettes.*
5
6
7

8 The argument this statement introduces is that e-cigarettes are driving increasing numbers of young people
9 to become nicotine addicted and to go on to become smokers. In fact experimentation with e-cigarettes
10 occurs predominantly among young people who have already started smoking or are at increased risk of
11 smoking[16, 17], thus representing a rational choice over the far more hazardous tobacco product. Most
12 importantly, smoking rates among teenagers in the US and UK are falling [18-22]. The same is true of adult
13 smoking, which is falling in both countries[23, 24], particularly rapidly in the UK as increasing numbers of
14 adult smokers switch to e-cigarettes[24]. Moreover, parental smoking is one of the main drivers of child
15 smoking uptake[22], so as e-cigarette use enables more adults to quit so fewer children will have smoking
16 parents as role models and more children will be protected from *in utero* and passive smoke exposure.
17
18
19
20
21
22
23
24
25
26
27
28
29
30

- 31 6. *Smokers see alternative nicotine delivery products as a viable alternative to the use of evidence-based*
32 *smoking cessation services and smoking cessation pharmacotherapy*
33
34
35
36
37

38 Smokers are correct to view e-cigarettes as a viable, evidence-based and proven option to aid smoking
39 cessation[4, 5] and the development of novel approaches for people who have tried conventional
40 pharmacotherapy unsuccessfully should be welcomed. It is also incorrect to regard e-cigarettes as an
41 *alternative* to engaging with smoking cessation services, given the compelling evidence that combining
42 psychological support with nicotine replacement increases quit rates. It is precisely the exclusion of people
43 who are choosing to try to quit smoking using e-cigarettes that is likely to reduce these individuals' chances
44 of success. Most importantly, although the Statement argues that smoking cessation services “exist”, in
45 practice provision of smoking cessation services is limited[25, 26], more so given political choices to pursue
46 austerity policies which reduce public health funding. Access to such services may therefore be difficult,
47 especially for the most disadvantaged people and those with disorganised lives. Rejection of harm reduction
48 strategies is thus likely to worsen health inequalities.
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

7. The tobacco harm reduction strategy is based on incorrect claims that we cannot curb the tobacco epidemic.

Harm reduction complements conventional tobacco control strategies, it does not replace them. The UK leads Europe in implementing tobacco control policies, including the exclusion of the tobacco industry from influence on policy making[27] and smoking rates there have declined faster than the rest of Europe as a result[28]. Combined with a rational and regulated approach to electronic cigarettes [Table 1] the UK is now experiencing rates of decline in smoking prevalence - from 20.2 in 2011 to 14.7% in 2018 - faster than for decades[24] and in England the ambition is to reduce smoking prevalence to below 5% across all groups by 2030. European countries in general, and the ERS in particular, should take heed of this evidence, rather than ignore it.

We believe that blanket opposition to e-cigarettes is misguided and will lead to a number of important consequences that are adverse to health. First, smokers who would otherwise have quit smoking by switching to a lower risk product will continue to smoke, and die prematurely from cancer, cardiovascular and respiratory disease. Second, people who have successfully switched to vaping may relapse to smoking if they come to believe that there is no health benefit from vaping, and thus increase their risk of avoidable morbidity and premature death. Third, the pursuit of arguments that vaping can't help people to quit smoking, in the face of clear evidence that it does, risks undermining public trust in science.

We wholeheartedly support the call for increased efforts to deliver “what we know works”. E-cigarette use is an epiphenomenon of smoking and current smoking levels are a consequence of past failures and delays in the implementation of tobacco control measures including effective and accessible treatment, tax increases, smokefree legislation, advertising bans and public health campaigns[29]. We respectfully suggest that the Society reconsiders its position, so that we can focus on our shared goal to make smoking history.

TABLE 1 Key messages for a rational approach to vaping and e-cigarettes

1	People smoke tobacco because of nicotine addiction, but the major harms come not from the nicotine but from toxic substances in the smoke.
2	Pharmacotherapy (e.g. dual NRT or varenicline) combined with psychological support should be made available to all smokers to help them to quit and should be considered as the first line approach.
3	E-cigarettes are an effective means to deliver nicotine, with a much lower risk of harm than continuing to smoke.
4	People who choose to use e-cigarettes to cut down or quit smoking should be offered psychological support and access to smoking cessation services.
5	People who choose to use e-cigarettes should be advised that they need to switch <i>completely</i> in order to derive substantial health benefits.
6	People using e-cigarettes should be advised to try to quit them too in the long term, but not at the risk of relapsing to smoking.
7	Never-smokers should avoid e-cigarettes.
8	E-cigarettes should continue to be subject to restrictions on age of sale, on advertising and on the strength of e-liquids, as set out in the EU Tobacco Products Directive.
9	Respiratory clinicians must continue to campaign for the full implementation of the WHO MPOWER strategy[30] designed to assist implementation of the Framework Convention on Tobacco Control, as this is the most powerful tool to deliver a smokefree generation. <ul style="list-style-type: none"> • Monitor tobacco use and prevention policies • Protect people from tobacco smoke • Offer help to quit tobacco use • Warn about the dangers of tobacco use • Enforce bans on tobacco advertising, promotion and sponsorship • Raise taxes on tobacco

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ACKNOWLEDGEMENTS

No specific financial support was received for this publication.

The authors have no conflicts of interest related to this work. SA chairs the Royal College of Physicians Tobacco Advisory Committee, NSH is Chair of Action on Smoking and Health (ASH UK).

REFERENCES

1. Pisinger C, Dagli E, Filippidis FT, Hedman L, Janson C, Loukides S, Ravara S, Saraiva I, Vestbo J. ERS and tobacco harm reduction. *European Respiratory Journal* 2019; 54(6): 1902009.

2. World Health Organization Regional Office for Europe. Data and Statistics: Current tobacco smoking in Europe. World Health Organisation, 2019.

3. National Institute for Health and Care Excellence. Tobacco: harm-reduction approaches to smoking (PH45). NICE, 2013.

4. Hajek P, Phillips-Waller A, Przulj D, Pesola F, Myers Smith K, Bisal N, Li J, Parrott S, Sasieni P, Dawkins L, Ross L, Goniewicz M, Wu Q, McRobbie HJ. A Randomized Trial of E-Cigarettes versus Nicotine-Replacement Therapy. *New England Journal of Medicine* 2019; 380(7): 629-637.

5. Walker N, Parag V, Verbiest M, Laking G, Laugesen M, Bullen C. Nicotine patches used in combination with e-cigarettes (with and without nicotine) for smoking cessation: a pragmatic, randomised trial. *The Lancet Respiratory Medicine* 2020; 8(1): 54-64.

6. Action on Smoking and Health. Use of e-cigarettes among adults in Great Britain, 2019. <https://ashorguk/information-and-resources/fact-sheets/statistical/use-of-e-cigarettes-among-adults-in-great-britain-2019/> 2019.

7. Beard E, West R, Michie S, Brown J. Association of prevalence of electronic cigarette use with smoking cessation and cigarette consumption in England: a time-series analysis between 2007 and 2017. *Addiction* 2020.

- 1
2 8. Britton J, Bogdanovica I. Electronic cigarettes. A report commissioned by Public Health England.
3
4 Public Health England, 2014.
5
- 6 9. Public Health England. E-cigarettes: a developing public health consensus. Public Health England,
7
8 2016.
9
- 10 10. National Academies of Sciences Engineering and Medicine. Public Health Consequences of E-
11
12 Cigarettes. 2018.
13
- 14 11. Tobacco Advisory Group of the Royal College of Physicians. Nicotine without smoke—tobacco harm
15
16 reduction. . <https://www.rcplondon.ac.uk/projects/outputs/nicotine-without-smoke-tobacco-harm-reduction>
17
18 (accessed 10-01-2020) 2016.
19
- 20 12. Goniewicz ML, Knysak J, Gawron M, Kosmider L, Sobczak A, Kurek J, Prokopowicz A, Jablonska-
21
22 Czapla M, Rosik-Dulewska C, Havel C, Jacob P, Benowitz N. Levels of selected carcinogens and toxicants in
23
24 vapour from electronic cigarettes. *Tobacco Control* 2014; 23(2): 133-139.
25
26
- 27 13. George J, Hussain M, Vadiveloo T, Ireland S, Hopkinson P, Struthers AD, Donnan PT, Khan F, Lang
28
29 CC. Cardiovascular Effects of Switching From Tobacco Cigarettes to Electronic Cigarettes. *Journal of the*
30
31 *American College of Cardiology* 2019; 74(25): 3112-3120.
32
33
- 34 14. Shahab L, Goniewicz ML, Blount BC, et al. Nicotine, carcinogen, and toxin exposure in long-term e-
35
36 cigarette and nicotine replacement therapy users: A cross-sectional study. *Annals of Internal Medicine*
37
38 2017.
39
- 40 15. Centers for Disease Control and Prevention. Outbreak of Lung Injury Associated with the Use of E-
41
42 Cigarette, or Vaping, Products. [https://www.cdc.gov/tobacco/basic_information/e-cigarettes/severe-lung-](https://www.cdc.gov/tobacco/basic_information/e-cigarettes/severe-lung-disease.html)
43
44 [disease.html](https://www.cdc.gov/tobacco/basic_information/e-cigarettes/severe-lung-disease.html) (accessed 10 Jan 2020) 2020.
45
46
- 47 16. Action on Smoking and Health. Use of electronic cigarettes among young people in Great Britain,
48
49 2019. <https://ashorguk/wp-content/uploads/2019/06/ASH-Factsheet-Youth-E-cigarette-Use-2019pdf> 2019.
50
51
- 52 17. West R, Brown J, Jarvis M. Epidemic of youth nicotine addiction? What does the National Youth
53
54 Tobacco Survey reveal about high school e-cigarette use in the USA? (Preprint)(Preprint Version 3). *Qeios*
55
56 *doi:10.32388/7450763* 2019.
57
58
59
60

1
2 18. NHS Digital. Smoking drinking and drug use among young people in England in 2018. NHS Digital,
3
4 London, 2019.
5
6 19. Gentzke AS, Creamer M, Cullen KA, Ambrose BK, Willis G, Jamal A, King BA. Vital Signs: Tobacco
7
8 Product Use Among Middle and High School Students—United States, 2011–2018. *Morbidity and Mortality*
9
10 *Weekly Report*, 2019; p. 157.
11
12 20. Wang TW, Gentzke AS, Creamer MR, Cullen KA, Holder-Hayes E, Sawdey MD, Anic GM, Portnoy DB,
13
14 Hu S, Homa DM. Tobacco Product Use and Associated Factors Among Middle and High School Students—
15
16 United States, 2019. *MMWR Surveillance Summaries* 2019; 68(12): 1.
17
18 21. Hopkinson NS, Lester-George A, Ormiston-Smith N, Cox A, Arnott D. Child uptake of smoking by
19
20 area across the UK. *Thorax* 2014; 69(9): 873-875.
21
22 22. Lavery AA, Filippidis FT, Taylor-Robinson D, Millett C, Bush A, Hopkinson NS. Smoking uptake in UK
23
24 children: analysis of the UK Millennium Cohort Study. *Thorax* 2018: thoraxjnl-2018-212254.
25
26 23. Centers for Disease Control and Prevention. Current Cigarette Smoking Among Adults in the United
27
28 States. 2019.
29
30 24. Office for National Statistics. Adult Smoking Habits in Great Britain 2018. Office for National
31
32 Statistics, 2019.
33
34 25. Royal College of Physicians. Hiding in plain sight: Treating tobacco dependency in the NHS
35
36 <https://www.rcplondon.ac.uk/projects/outputs/hiding-plain-sight-treating-tobacco-dependency-nhs>; 2018.
37
38 26. Filippidis FT, Lavery AA, Mons U, Jimenez-Ruiz C, Vardavas CI. Changes in smoking cessation
39
40 assistance in the European Union between 2012 and 2017: pharmacotherapy versus counselling versus e-
41
42 cigarettes. *Tobacco Control* 2019; 28(1): 95-100.
43
44 27. Joossens L, Raw M. The Tobacco Control Scale 2016 in Europe. Association of European Cancer
45
46 Leagues, Brussels, 2017.
47
48 28. Feliu A, Filippidis FT, Joossens L, Fong GT, Vardavas CI, Baena A, Castellano Y, Martinez C, Fernandez
49
50 E. Impact of tobacco control policies on smoking prevalence and quit ratios in 27 European Union countries
51
52 from 2006 to 2014. *Tob Control* 2019; 28(1): 101-109.
53
54
55
56
57
58
59
60

- 1
2 29. Hopkinson NS. The prominence of e-cigarettes is a symptom of decades of failure to tackle smoking
3
4 properly. *BMJ* 2019; 364: l647.
5
6 30. Dubray J, Schwartz R, Chaiton M, O'Connor S, Cohen JE. The effect of MPOWER on smoking
7
8 prevalence. *Tobacco Control* 2015; 24(6): 540-542.
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60